The possibility and prospects of using cytostatics in patients with COVID-19 on the example of cyclophosphamide
- Авторлар: Tsvetov V.M1, Burashnikova I.S2, Sychev D.A3, Poddubnaya I.V3
-
Мекемелер:
- Federal Center for Cardiovascular Surgery
- Kazan State Medical Academy - branch of the Russian Medical Academy of Continuous Professional Education
- Russian Medical Academy of Continuous Professional Education
- Шығарылым: Том 28, № 1 (2021)
- Беттер: 10-13
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313050
- DOI: https://doi.org/10.18565/pharmateca.2021.1.10-13
- ID: 313050
Дәйексөз келтіру
Ашық рұқсат
Рұқсат берілді
Аннотация
Currently, there is no evidence-based data to recommend the use of cyclophosphamide for the treatment of patients with COVID-19. The use of this drug may interfere with the course of SARS-CoV-2 infection, including development of adverse side effects. Clinical trials are required to evaluate the efficacy and safety of cytostatics, including cyclophosphamide, in patients with COVID-19.
Негізгі сөздер
Толық мәтін
Авторлар туралы
V. Tsvetov
Federal Center for Cardiovascular Surgery
I. Burashnikova
Kazan State Medical Academy - branch of the Russian Medical Academy of Continuous Professional Education
D. Sychev
Russian Medical Academy of Continuous Professional Education
I. Poddubnaya
Russian Medical Academy of Continuous Professional Education
Әдебиет тізімі
- Клиническая фармакология: национальное руководство. Под ред. Ю.Б. Белоусова, В.Г Кукеса, В.К. Лепахина, В.И. Петрова. М., 2009. 976 с. [Clinical pharmacology: national guidelines. Ed. by Yu.B. Belousov, V.G. Kukes, V.K. Lepakhin, VJ. Petrov. M., 2009. 976 p. (In Russ.)].
- Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020;20(5):269-70. doi: 10.1038/s41577-020-0308-3.
- Misra D.P, Agarwal V, Gasparyan A.Y., Zimba O. Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol. 2020;39(7): 2055-62. doi: 10.1007/s10067-020-05073-9.
- Государственный реестр лекарственных средств [Электронный ресурс]. [State Register of Medicines [Electronic resource]. (In Russ.)]. URL: http://grls.rosminzdrav.ru/Grls_View_ v2.aspx?routingGuid=0873b1f1-dc7c-452e-97c4-595469758127&t=.
- National Library of Medicine (NLM) [Electronic resource]. URL: https://clinicaltrials.gov/ct_2/ results?term=co vid+or+SARS-CoV-2&cond=Covi d19&intr=Cytostatic#.
- EU Clinical Trials Register [Electronic resource]. URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=Cyclophosphamid&phase =phase-one&phase=phase-two&phase=phase-three&phase=phase-four&dateFrom=2020-01- 01&dateTo=2020-12-23.
- Hosoba R., et al. COVID-19 pneumonia in a patient with adult T-cell leukemia-lymphoma. J. Clin Exp Hematopathol. 2020;60(4):174-78. doi: 10.3960/jslrt.20030.
- Khurana A., Saxena S. Immunosuppressive agents for dermatological indications in the ongoing COVID 19 pandemic: rationalizing use and clinical applicability. Dermatol Ther. 2020;33(4):e13639. doi: 10.1111/dth.13639.
- Al Saleh A.S., et al. Multiple Myeloma in the Time of COVID-19. Acta Haematol. 2020;143(5):410-6. doi: 10.1159/000507690.
- Brocato R.L., et al. Disruption of Adaptive Immunity Enhances Disease in SARS-CoV-2-Infected Syrian Hamsters. J. Virol. 2020;94(22):e01683-20. doi: 10.1128/JVI.01683-20.
- Revannasiddaiah S., et al. A potential role for cyclophosphamide in the mitigation of acute respiratory distress syndrome among patients with SARS-CoV-2. Med. Hypoth. 2020;144:109850. doi: 10.1016/j.mehy.2020.109850.
- El Fakih R., Hashmi S.K., Ciurea S.O., et al. Posttransplant cyclophosphamide use in matched HLA donors: a review of literature and future application. Bone Marrow Transplant. 2020;55:40-7. doi: 10.1038/s41409-019-0547-8.
- Mayumi H., Umesue M., Nomoto K. Cyclophosphamide-induced immunological tolerance: an overview. Immunobiol. 1996;195:129-39. doi: 10.1016/S0171-2985(96)80033-7.
- Luznik L., O’Donnell P.V., Fuchs E.J. Posttransplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012;39:683-93.
- da Rocha A.P, et al. Covid-19 and patients undergoing pharmacological treatments for immune-mediated inflammatory diseases: protocol for a rapid living systematic review. doi: 10.1101/2020.05.01.20087494.
- Harma VK., Khandpur S. Evaluation of cyclophosphamide pulse therapy as an adjuvant to oral corticosteroid in the management of pemphigus vulgaris. Clin Exp Dermatol. 2013;38:659-64. doi: 10.1111/ced.120 73.
- Carette S., Klippel J.H., Decker J.L., et al. Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up. Ann Intern Med. 1983;99:1-8. doi: 10.7326/00034819-99-1-1.
- Austin H.A., KlippelJ.H., Balow J.E., et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314:614-9. doi: 10.1056/NEJM198603063141004.
- De Groot K. Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Ann Intern Med. 2009:150(10):670. doi: 10.7326/0003-4819-150-10-200905190 00004.
Қосымша файлдар
